Aspire Biopharma Holdings, Inc. 8-K

What Happened

• Aspire Biopharma Holdings, Inc. (ticker: ASBP) filed a Form 8-K on April 20, 2026 reporting a Regulation FD disclosure. The company furnished (not filed) a press release dated April 20, 2026 as Exhibit 99.1 and incorporated it by reference in the report.

Key Details

• Item reported: 7.01 — Regulation FD Disclosure (press release furnished as Exhibit 99.1).
• Item reported: 9.01 — Exhibits include 99.1 (Press Release dated April 20, 2026) and 104 (Cover Page Interactive Data File/XBRL).
• The 8-K furnishes the press release (legal distinction: “furnished” means it is provided to the SEC but not subject to certain liabilities that apply to “filed” disclosures).
• The filing does not include separate financial statements, earnings figures, executive changes, mergers, or bankruptcies.

Why It Matters

• Regulation FD disclosures are used to ensure material information is shared publicly and simultaneously; investors should review the furnished press release for any material updates from Aspire Biopharma.
• Because the 8-K itself does not include financial results or other substantive items, investors seeking details (e.g., earnings, revenue, CEO or transaction news) should read the Exhibit 99.1 press release or check the company’s SEC filings and investor relations page for additional documents.